VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs
- May 2, 2025
- 1 min read
Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the BiTAC AND-gating platform the company uses to improve on the precision of T-cell engagers and antibody-drug conjugates.
.png){kind=logo}